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TO THE EDITORThe Role of
Pro-Fibrotic Biomarkers
in Atrial Fibrillation
How Good Are We in the
Translational Interpretation?We read with interest the paper by Takemoto et al. (1),
where the translational aspect of proﬁbrotic bio-
markers in atrial ﬁbrillation (AF) is discussed. The
authors showed higher intracardiac levels of galectin-
3 in patients with persistent AF compared with
paroxysmal AF as well as a signiﬁcant association
between galectin-3 levels and arrhythmia recurrences
after catheter ablation. Furthermore, in an animal
model, the authors analyzed the role of GM-CT-01
inhibitor and showed a signiﬁcant reduction of
galectin-3 and transforming growth factor (TGF)–b1
levels, indicating protective effects on proﬁbrotic
processes in ﬁbrillating atria.
The authors should be congratulated for their
interesting translational research and the promising
aspects of a potential upstream therapy in AF.
Nevertheless, we have some comments, mainly on
the basis of our and other studies.
Several clinical and experimental studies have
highlighted the role of interstitial ﬁbrosis in the
initiation and maintenance of AF (2). Atrial ﬁbrosis
might disturb anisotropic conduction and change the
duration and dispersion of the effective refractory
period. This explains the intra-atrial re-entry circuits
leading to the electrophysiological and structural
remodeling in atrial tissue that facilitates AF initia-
tion and perpetuation. Besides the proinﬂammatory
state, the proﬁbrotic pathway is the most plausible
cause for arrhythmia recurrences following catheter
ablation so far (3). There are several proﬁbrotic
markers of great interest that may be associated with
rhythm outcome. Different studies have suggested
that TGF-b1 is involved in the mechanisms of atrial
ﬁbrosis and AF pathogenesis, and plasma TGF-b1
levels might be considered as a surrogate marker for
atrial ﬁbrosis (2). Because of its involvement in pro-
ﬁbrotic remodeling and inﬂammation, galectin-3 is
one of the emerging biomarkers in different cardiacdiseases and gains recent attention as a novel
biomarker in AF.
What is the clinical reality when we try to translate
hypotheses from experimental studies? Several clin-
ical studies have aimed to analyze the role of galectin-
3 in AF, but the results are not consistent (4). In
contrast to the current study (1), we found signiﬁ-
cantly higher levels of proinﬂammatory and proﬁ-
brotic biomarkers in peripheral blood than in cardiac
circulation (J. Kornej et al., unpublished data, April
2016)—probably indicating the washout phenomenon.
Also, we could not ﬁnd any signiﬁcant differences in
galectin-3 levels in a subgroup of patients with blood
taken from different cardiac sites (4). Furthermore,
higher galectin-3 levels found in AF patients might be
mediated by cardiometabolic disturbances rather
than by heart rhythm itself, which is in accordance
with other studies (4). Finally, galectin-3 was not
useful to predict arrhythmia recurrences (4,5).
Similar inconsistency regarding prediction of
arrhythmia recurrences had also been shown in clinical
studies with TGF-b1. For example, despite its known
role in the pathophysiology of cardiac ﬁbrosis, TGF-b1
failed to improve the value of widely used clinical
scores for the prediction of arrhythmia recurrences (3).
In conclusion, it remains challenging to translate
the ﬁndings from experimental settings to “real-
world” (multi)morbid patients.*Jelena Kornej, MD
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How Good Are We in the Translational Interpretation?We appreciate the interest of Drs. Kornej and Boll-
mann in our work, and their kind words about our
recent paper (1). For the most part, their letter focuses
on the challenge of translating our experimental
ﬁndings “to ‘real-world’ (multi)morbid patients.”
In criticizing our paper, Drs. Kornej and Bollmann
base their arguments on both unpublished data and a
published study (2) in which they were unable to ﬁnd
any differences in galectin (Gal)-3 levels in blood from
the left atrium, the coronary sinus, and a peripheral
vein. They concluded that higher Gal-3 levels in
patients with atrial ﬁbrillation (AF) are likely to be
mediated by cardiometabolic disturbances rather
than by AF itself.
One cannot argue with unpublished data, which
remain anecdotal. However, we can look at their
published data that do show higher Gal-3 levels
in blood from their AF cohort relative to their AF-free
cohort (2), which is a result that certainly agrees with
ours. However, unlike our data, Kornej et al. (2) found
no relationship between Gal-3 levels and AF recur-
rence. Here, we argue, the difference was in experi-
mental design. The elevated CHADS2 (congestive
heart failure, hypertension, age $75 years, diabetes,
previous stroke) and CHA2DS2-VASc (congestive heart
failure, hypertension, age $75 years, diabetes, pre-
vious stroke, vascular disease, age 65 to 74 years, sex
category [female]) scores of their AF patients sug-
gested that they had signiﬁcant comorbidities, which
may have confused the results. Notably, our transla-
tional approach, which was on the basis of a large
animal model of lone AF with no heart failure or other
comorbidities, required speciﬁc exclusion criteria in
our patients. This enabled us to focus on biomarkers
related to AF-related changes in the absence of
comorbidities. Consequently, our data speak for
themselves: experimentally they demonstrate for the
ﬁrst time that Gal-3 mediates sustained AF-induced
atrial structural and electrical remodeling and con-
tributes to AF perpetuation (1). In selected patients,
intracardiac serum Gal-3 levels were greater in
persistent than paroxysmal AF, and the Gal-3 levelwas an independent predictor of AF recurrences after
a single ablation procedure (1).
Now, coming back to the issue of “’real-world’
(multi)morbid patients,” we are not disputing the
importance of considering Gal-3 as a marker of car-
diometabolic disease. In fact, Gal-3 has been shown to
be involved in many diseases; recent studies have
focused on the effects of Gal-3 on adipocytes, and it is
difﬁcult to exclude the importance of obesity in the
pathogenesis of AF (3). However, it is again essential
to recall that our tachypacing model leads to Gal-3
elevation and persistent AF unaffected by comorbid-
ities, which strongly supports the involvement of
Gal-3 in the mechanism of AF progression and AF
recurrence after ablation. In this regard, Drs. Kornej
and Bollmann seem to have missed the paper by Wu
et al. (4), which also reported that patients who
experienced recurrences after AF ablation had
signiﬁcantly higher Gal-3 levels in peripheral vein
blood (p ¼ 0.007) than those who did not experience
such recurrences. One important difference among
the 3 studies was the length of the follow-up period.
In the study by Kornej et al. (2), the follow-up period
was reported to be 6 months; Wu et al. (4) followed
their patients for about 17 months; and we (1) used a
12-month follow-up period. Although in the report by
Kornej et al. (2) Gal-3 levels did not correlate with AF
recurrences, in the latter 2 studies it did, and very
strongly. Therefore, it seems likely that longer follow-
up periods might be necessary to see a relation
between Gal-3 and AF recurrence outcome after
catheter ablation.
Finally, we certainly agree that translating labo-
ratory observations to clinical utility is challenging
and requires caution. Effective translational research
is hampered by a poor understanding of the biology
of disease. Notably, despite more than 100 years of
progress in basic research in AF biology, today we
do not adequately understand the pathogenesis of
human AF. To our knowledge, our study is the ﬁrst
of its kind to address it systematically, aiming to
understand how human AF perpetuation, apparent
at the whole-organism scale, emerges from molecu-
lar, cellular, tissue, organ, and organ-system in-
teractions. Therefore, we submit that our study is a
clear example of successful translational research,
which is a function of not only the quality of the
science, but also appropriate design and effective
collaboration between the scientist and the
clinician.Yoshio Takemoto, MD, PhD
Kuljeet Kaur, PhD
Hakan Oral, MD, PhD
